<DOC>
	<DOCNO>NCT00383331</DOCNO>
	<brief_summary>This study design evaluate Pemetrexed Gemcitabine Day 1 follow Gemcitabine Day 8 every 21 day ( Arm A ) Pemetrexed Gemcitabine Day 1 every 14 day ( Arm B ) patient NSCLC . Each agent sequence well demonstrated antitumor activity respectively patient locally advance metastatic NSCLC . Therefore , reasonable investigate optimal schedule combination , combination associate anti-tumor activity phase II arena .</brief_summary>
	<brief_title>Pemetrexed Gemcitabine Every 14 Days Versus Every 21 Days Advanced Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>histologic cytologic diagnosis NSCLC Stage IIIB IV prior systemic chemotherapy advance NonSmall Cell Lung Cancer Prior radiotherapy must complete least 4 week study enrollment . estimate life expectancy 12 week serious cardiac condition , myocardial infarction within 6 month , angina , heart disease document brain metastasis unless patient complete successful local therapy central nervous system metastases corticosteroid least 2 week enrollment significant weight loss ( , &gt; 10 % ) previous 6 week study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>